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ABSTRACT
The study of long noncoding RNAs (lncRNAs) is an emerging area of cancer 
research, in part due to their ability to serve as disease biomarkers. However, few 
studies have investigated lncRNAs in chronic lymphocytic leukemia (CLL). We have 
identified one particular lncRNA, treRNA, which is overexpressed in CLL B-cells. We 
measured transcript expression in 144 CLL patient samples and separated samples 
into high or low expression of treRNA relative to the overall median. We found that 
high expression of treRNA is significantly associated with shorter time to treatment. 
High treRNA also correlates with poor prognostic indicators such as unmutated IGHV 
and high ZAP70 protein expression. We validated these initial findings in samples 
collected in a clinical trial comparing the nucleoside analog fludarabine alone or 
in combination with the alkylating agent cyclophosphamide in untreated CLL 
samples collected prior to starting therapy (E2997). High expression of treRNA was 
independently prognostic for shorter progression free survival in patients receiving 
fludarabine plus cyclophosphamide. Given these results, in order to study the role 
of treRNA in DNA damage response we generated a model cell line system where 
treRNA was over-expressed in the human B-CLL cell line OSU-CLL. Relative to the 
vector control line, there was less cell death in OSU-CLL over-expressing treRNA 
after exposure to fludarabine and mafosfamide, due in part to a reduction in DNA 
damage. Therefore, we suggest that treRNA is a novel biomarker in CLL associated 
with aggressive disease and poor response to chemotherapy through enhanced 
protection against cytotoxic mediated DNA damage.
Research Paper
Oncotarget25943www.impactjournals.com/oncotarget
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a B-cell 
malignancy with a heterogeneous clinical course. 
While some patients have indolent disease that may not 
require therapy for years, others progress quite rapidly. 
Presently, biomarkers such as unmutated IGHV, ZAP70 
expression, and cytogenetic deletion of 17p or 11q have 
been identified as independent markers for aggressive 
disease [1-4]. However, these markers are insufficient 
to demarcate all aggressive cases. Identifying additional 
molecular markers that predict for aggressive disease 
or that defines a potentially different biology remains of 
considerable interest, particularly those which can predict 
response to treatment.
Gene expression can be a useful prognostic indicator 
in CLL, particularly the expression of noncoding RNAs 
such as microRNAs (miRs). Several miRs have been 
shown to play critical biological roles in CLL, particularly 
in cell signaling. For example, mir-155 expression 
enhances sensitivity to B-cell receptor (BCR) ligation [5], 
and high expression of miR-155 is associated with shorter 
overall survival and progression free survival with chemo-
immunotherapy [5, 6]. Conversely, miR-150 expression 
has been shown to decrease the intensity of BCR signaling 
[7]. Calin et. al has described a 9 miR signature associated 
with decreased time to treatment (TTT) in CLL that 
includes mirR-181a (high), miR-155 (high), miR-146 
(high), and miR-29c (low) [8]. Negative regulators of the 
anti-apoptotic protein BCL2, miR-15 and miR-16, are 
often chromosomally deleted or downregulated in CLL 
[9, 10]. While the expression of miRs has been clearly 
demonstrated as important in CLL, the contribution of 
other noncoding RNAs has not been well established 
in this disease. Recently, it has been shown that long 
noncoding RNAs (lncRNAs; defined as noncoding 
transcripts greater than 200 nucleotides in length) are 
able to regulate gene expression and are associated with 
diverse biological processes [11, 12]. The deregulated 
expression of lncRNAs such as HOTAIR, MALAT1, and 
SChLAP1 have been associated with disease progression 
in multiple types of cancer [13-18]. Specifically in CLL, 
differential expression of lncRNAs has been identified 
across molecular subgroups as well as compared to normal 
B-cells [19, 20]. Even so, few functional studies have been 
done to determine the role of lncRNAs in CLL disease 
mechanism although they likely play a significant part in 
this process. Some examples include linc-p21 and NEAT1, 
which have been shown to be induced by DNA damage in 
a p53 dependent mechanism in CLL cells [21]. In addition, 
circulating levels of linc-p21 in plasma from CLL patients 
is lower than healthy donor controls [22].
In the current study, we explored the differential 
expression of lncRNAs in CLL and identified treRNA 
(TRERNA1), as overexpressed in CLL and associated 
with poor prognosis. TreRNA has been described to have 
enhancer-like function as well as translational regulatory 
functions, and is overexpressed in breast cancer lymph-
node metastases and colon cancer [23, 24]. In CLL, we 
found high expression of treRNA was associated with 
poor response to chemotherapy independent of other 
variables, and suggest that treRNA may serve as a valuable 
prognostic factor in this disease. Finally, using a CLL 
cell line model we show that over-expression of treRNA 
results in decreased DNA damage caused by exposure 
to chemotherapeutic agents, likely contributing to the 
impaired response and decreased clinical benefit observed 
in patients receiving these agents.
RESULTS
lncRNAs are differentially expressed in CLL
We first sought to explore if lncRNAs are 
differentially expressed in CLL by comparing pooled 
RNA isolated from CLL B-cells to pooled RNA from 
healthy donor peripheral blood B-cells, with and without 
stimulation with CD40 ligand. This was done using the 
ArrayStar human lncRNA microarray, a platform that 
analyzes over 30,000 lncRNA transcripts in addition 
to 30,000 coding transcripts. 2418 probes, including 
both mRNA and lncRNA, were significantly different 
between CLL and normal B-cells at a FDR = 10% 
(Supplementary Figure 1). We chose 14 transcripts 
annotated as lncRNA for further validation, selected based 
on the degree of differential expression and potential 
relevance to cancer based on previous publications. We 
analyzed these targets in an additional 14 CLL samples 
and 5 normal B-cell samples (independent of those 
used in the microarray), and were able to validate 8 
lncRNAs as having significantly different expression 
when comparing CLL samples to normal B-cell samples 
(Figure 1A). In addition, two of these lncRNAs, treRNA 
and ENST00000413901, exhibited significantly higher 
expression in the unmutated IGHV samples compared to 
mutated (Figure 1B; p = 0.0395 for treRNA and p = 0.0125 
for ENST00000413901). Based on this potential relevance 
to aggressive CLL disease, we further investigated the 
prognostic significance of these two lncRNAs in a large 
well-characterized cohort of patient samples.
High expression of treRNA is associated with 
shorter time to treatment
The initial set of CLL samples used to assess 
prognostic significance of treRNA and ENST00000413901 
(abbreviated 3901) were obtained from 144 previously 
untreated asymptomatic CLL patients enrolled in the CRC 
registry. In this particular patient set, both ZAP70 protein 
expression and methylation status (a surrogate marker 
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for Zap70 expression) has been previously described 
[4]. Expression of treRNA and ENST00000413901 
were measured using qRT-PCR and normalized to the 
housekeeping gene TBP. We separated patient samples into 
high or low expression of treRNA and ENST00000413901 
based on the median expression value within the set. We 
found that high expression of treRNA associated with poor 
prognostic indicators: low ( < 20%) ZAP70 methylation 
Table 1: TreRNA is associated with aggressive disease markers in the CRC patient set
Variable Low treRNA (n = 72)
High treRNA
 (n = 72) P-value
Median Age, yrs. (Range) 53 (32-78) 52 (26-82) 0.33
Female, Num. (%) 18 (25) 26 (36) 0.21
ZAP70 Methylation, Num. (%)
   Low
   High (> 20%)
44 (61)
28 (39)
63 (88)
9 (13) <0.001
ZAP70 Protein Expression, Num. (%)
   Negative
   Positive (>20%)
45 (63)
27 (38)
26 (36)
46 (64) 0.003
CD38 Expression, Num. (%)
   Negative
   Positive (>20%)
39 (54)
33 (46)
31 (43)
41 (57) 0.24
IGHV, Num. (%)
   Mutated
   Unmutated (>98%)
29 (40)
43 (60)
8 (11)
64 (89) <0.001
Associations were tested using the Wilcoxon rank sum and Fisher’s exact tests. Abbreviations: yrs, years; num, number; del, 
deletion.
Figure 1: LncRNAs are aberrantly expressed in CLL. a. Relative expression of lncRNAs in primary CLL cells compared to 
normal B cells measured by qRT-PCR. P-values were determined by linear mixed effects models. b. Relative expression of treRNA and 
ENST00000413901 in IGHV unmutated (black) compared to IGHV mutated (red) primary CLL cells. Gray dots are samples with unknown 
mutational status. DeltaCT = (lncRNA CT - housekeeping gene CT). P-values were determined by two-sided t-tests; p = 0.0395 for 
ENST00000413901 and p = 0.0125 for treRNA.
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(p < 0.001), high ( > 20%) ZAP70 protein expression 
(p = 0.003), and unmutated IGHV (p < 0.0001) (Table 
1). High expression of treRNA also associated with 
shorter TTT across the entire dataset (p = 0.04, Figure 
2A). Interestingly, high expression of treRNA identified 
patients with shorter TTT within two different favorable 
prognostic subgroups: low CD38 expression (p= 0.006, 
Figure 2B) and low ZAP70 protein expression (p = 
0.05, Figure 2C). Although lncRNA ENST00000413901 
was also associated with poor prognostic indicators low 
ZAP70 methylation, high ZAP70 protein expression, and 
unmutated IGHV (data not shown), it was not as strongly 
associated with TTT. Of these two lncRNAs, treRNA 
exhibits better correlation with CLL disease markers, and 
the transcript has been previously well characterized. We 
therefore focused our remaining correlative and functional 
studies on treRNA.
High expression of treRNA independently predicts 
shorter progression free survival in patients 
receiving chemotherapy
While interrogating the clinical significance of 
treRNA we discovered that CLL cells contain a transcript 
in the nuclear RNA fraction that retains the intron 
between the two coding exons, likely due to insufficient 
splicing (Supplementary Figure 2A & 2B). Therefore we 
investigated the prognostic significance of both spliced 
and retained intron treRNA (ri-treRNA) in a second, 
independent dataset. For this we used 147 (pre-treatment) 
samples from symptomatic, previously untreated patients 
enrolled in the Eastern Cooperative Oncology Group 
E2997 (E2997) phase III clinical trial comparing the 
nucleoside analog fludarabine to the combination of 
fludarabine plus the alkylating agent cyclophosphamide 
[25]. In this setting, we confirmed the association between 
high expression of treRNA and unmutated IGHV (p = 
0.0029), and identified an additional association with 
cytogenetic markers; namely high treRNA expression 
occurred more frequently in patients with deletion 17p, 
and less frequently with trisomy 12 (p = 0.018) (Table 2). 
High treRNA was also associated with shorter PFS (p < 
0.0001; Figure 3A) and overall survival (OS) (p < 0.0001; 
Figure 3B). Even though ri-treRNA expression correlates 
with treRNA expression (Supplementary Figure 3A), 
these associations were not significant for the unspliced 
transcript (Supplementary Figure 3B). This could be 
related to the fact that patients express considerably lower 
levels of ri-treRNA compared to spliced treRNA and have 
a smaller dynamic range of expression. We next included 
treRNA expression in a multivariable model which 
has been previously described for this dataset [26, 27]. 
TreRNA expression did not add prognostic information 
for OS in the multivariable model once accounting for 
treatment arm, age, and molecular group. However, the 
impact of treRNA on PFS was significantly different 
depending on whether patients received fludarabine plus 
cyclophosphamide or fludarabine alone (p = 0.01) (Figure 
3C). In a model accounting for the effect modification of 
treatment arm on the relationship between treRNA and 
PFS and adjusting for age, sex, Rai stage, and molecular 
group, high treRNA expression was strongly associated 
with a higher risk of progression or death in the group who 
received fludarabine plus cyclophosphamide (HR 3.14, 
95% CI 1.61-6.14, p = 0.0008). For those who received 
fludarabine alone, PFS was short irrespective of treRNA 
expression (HR 1.12, 95% CI 0.62-2.02, p = 0.70). 
The presence of treRNA results in less DNA 
damage with fludarabine and mafosfamide
The inferior progression-free survival with 
fludarabine plus cyclophosphamide in patients with 
high treRNA expression suggests a role for treRNA 
in mediating DNA damage response; therefore we 
established a stable retroviral system to further study 
this observation in vitro. We used the CLL cell line 
(OSU-CLL; previously established in our lab [28]) to 
exogenously express treRNA, as well as a control line 
transduced with the empty viral vector. Expression of 
treRNA did not alter baseline viability, proliferation, or 
migration (Supplementary Figure 4). When treated with 
chemotherapeutic agents, the treRNA cell line exhibited 
increased viability compared to the vector control 
when drugged with fludarabine at 5, 10, and 20uM; 
this protective effect diminished at 30uM (Figure 4A). 
Expression of treRNA was less protective to mafosfamide, 
a significant difference in viability between the treRNA and 
control cell line was seen only at the highest concentration 
of drug (10uM) (Supplementary Figure 5A). In OSU-CLL 
expressing treRNA, we observed a trend towards less 
induction of the DNA damage indicator, γH2AX, when 
exposed to fludarabine or fludarabine plus mafosfamide, 
but not mafosfamide alone (Figure 4B), although this did 
not reach statistical significance (Supplementary Figure 
5B). Therefore we verified the difference in DNA damage 
using the more quantifiable comet assay. Following one 
hour incubation with fludarabine, mafosfamide, or the 
combination, DNA damage was markedly less induced in 
all drugging conditions in OSU-CLL treRNA compared to 
empty vector, indicated by the shorter comet tails (Figure 
4C). Quantitation of the damage for 300 individual cells 
per condition (measured by olive tail moment) verified 
significantly less induction in the treRNA expressing cell 
line (p < 0.0001; Figure 4D). These results indicate that 
the presence of treRNA results in decreased DNA damage 
in cells exposed to chemotherapeutic agents.
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Figure 2: TreRNA is associated with time to treatment in CLL. Time to treatment in the a. CRC patient set b. CD38 negative 
patients, and c. ZAP70 protein expression negative patients. P-values were determined by the log-rank test.
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Figure 3: TreRNA is associated with progression-free survival in CLL. a. Progression-free survival, b. overall survival, and c. 
progression-free survival by treatment arm and by treRNA group. P-values were determined by the log-rank test.
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Figure 4: TreRNA expression impairs DNA damage following treatment with fludarabine and mafosfamide. a. 
Viability, measured by MTS, of OSU-CLL treRNA and OSU-CLL empty vector after 48 hours of fludarabine treatment. Data are shown 
with individual replicates and best fit lines. P-values were determined by linear mixed effects models. *, p = 0.002; **, p < 0.001. b. 
Representative immunoblot of γH2AX induction in OSU-CLL-treRNA versus empty vector cell lines following 24 hour treatment with 
fludarabine (F, 10uM), mafosfamide (M, 2.36uM) or a combination of fludarabine plus mafosfamide (F+M). Actin probed as a loading 
control. Image cropped to show relevant cell lines and controls. c. Representative images from comet assay after one hour of drugging with 
F, M, or F+M in OSU-CLL empty vector and OSU-CLL treRNA. d. Quantitation of comet assay using olive tail moment for 200 cells per 
each condition. P-values were determined by linear mixed effects models.
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DISCUSSION
Here we characterized the differential expression 
of lncRNA in CLL cells as compared to normal blood 
B-cells. While validating differentially expressed lncRNA 
identified by microarray, we narrowed our interest to two 
lncRNAs, treRNA and ENST00000413901, due to their 
variable expression in CLL patients and association with 
IGHV mutational status. Of these two, only treRNA was 
significantly associated with TTT in the initial prognostic 
dataset. While we did not pursue further studies with 
ENST00000413901, the clear separation of patients who 
highly express this lncRNA in contrast to patients with 
low to undetectable levels suggests that this lncRNA 
may reflect biologically distinct subgroups although such 
expression did not vary with clinical outcome.
Our initial dataset indicated that patients with high 
expression of treRNA are enriched for aggressive disease 
markers and required treatment earlier than those with 
lower expression. These findings were supported in a 
second, independent dataset that confirmed the association 
between treRNA and the aggressive IGHV unmutated 
disease, and also identified that treRNA expression 
is associated with shorter PFS and OS. Interestingly, 
we found low expression of treRNA expression was 
an independent prognostic factor for improved PFS in 
patients receiving fludarabine plus cyclophosphamide. 
TreRNA expression was not associated with PFS in 
patients receiving fludarabine alone, however, this 
arm of the study overall did very poorly. It would it 
be interesting to see if the prognostic significance of 
treRNA is specifically associated with therapy involving 
these DNA damaging agents and if this association with 
PFS will persist for patients receiving fludarabine plus 
cyclophosphamide in combination with rituximab, as this 
is a standard treatment strategy in CLL [29, 30]. Given 
that treRNA has been reported as expressed in breast 
cancer lymph-node metastases as well as colorectal cancer 
[24], and that chemotherapeutic agents are also used for 
treatment of these types of cancer, it would also be of 
interest to explore if treRNA expression is predictive of 
chemotherapeutic response in these solid tumors. 
The association with PFS of the combination 
treatment of fludarabine plus cyclophosphamide suggests 
that treRNA may play a role in response to DNA damaging 
agents, prompting further exploration of this. In vitro 
Table 2: TreRNA is associated with aggressive disease markers in the ECOG 2997 patient set
Variable Low treRNA (n = 74)
High treRNA
 (n = 73) P-value
Treatment Arm, Num. (%)
   Fludarabine (F)
   F+Cyclophosphamide (C)
37 (50)
37 (50)
38 (52) 
35 (48) 0.87
Median Age, yrs. (Range) 62 (33-83) 60 (42-78) 0.34
Female, Num. (%) 20 (27) 22 (30) 0.72
Rai Stage II/III/IV, Num. (%) 51 (69) 56 (77) 0.35
ZAP70 Methylation, Num. (%)
  Low
  High (>20%)
  Unknown
32 (70)
14 (30)
28
45 (79)
12 (21)
16
0.36
IGHV, Num. (%)
  Mutated
  Unmutated (>98%)
  Unknown
29 (49)
30 (51)
15
16 (23)
53 (77)
4
0.0029
Dohner Classification, Num. (%)
  del(17p)
  del(11q)
  +12
  del(6q)
  Normal
  del(13q)
  Unknown
2 (3)
8 (11)
25 (34)
1 (2)
13 (18)
24 (33)
1
11 (15)
11 (15)
12 (17)
4 (6)
11 (15)
22 (31)
2
0.018
Molecular Group, Num. (%)
  del(17p)
  del(11q)
  +12/Notch Mutated
  IGHV Unmutated
  Other
  Unknown
2 (3)
8 (13)
11 (18)
15 (25)
25 (41)
13
11 (16)
11 (16)
4 (6)
32 (48)
9 (13)
6
<0.0001
Associations were tested using the Wilcoxon rank sum and Fisher’s exact tests. Abbreviations: yrs, years; num, number; del, 
deletion.
Oncotarget25950www.impactjournals.com/oncotarget
studies using the OSU-CLL cell line expressing treRNA 
showed increased viability and a slight trend towards 
less induction of the DNA damage marker γH2AX. We 
validated this trend using the comet assay, which more 
readily quantifies DNA repair, and found that OSU-CLL 
expressing treRNA had markedly reduced induction of 
DNA damage after one hour exposure to fludarabine, 
mafosfamide, and the combination compared to OSU-CLL 
empty vector. Interestingly, these protective effects were 
more pronounced with fludarabine exposure compared 
to mafosfamide. These results suggest that treRNA may 
be directly involved in decreasing DNA damage after 
exposure to chemotherapeutic agents and provides a basis 
for why this marker is independently associated with PFS 
in patients who receive these agents. However, the cell 
line model may be unable to fully recapitulate what is 
happening in the patient cells due to inherent differences 
between cell lines and primary samples, the lack of 
microenvironment interactions in the in vitro setting, 
and this model does not address the role of treRNA with 
prolonged exposure to chemotherapeutic agents.
TreRNA has been reported to affect both 
transcription and translation; however, the targets of 
treRNA may be cell type specific [23, 24]. In normal 
B-cells treRNA was low to undetectable; however, in CLL 
patients samples we found a wide range of expression. 
High treRNA expression in CLL correlated with poor 
prognostic markers suggesting that treRNA expression 
is part of an aggressive B-cell leukemia phenotype. 
However, the factors that drive the expression of treRNA, 
and functional effects of treRNA outside of DNA damage 
response in CLL, remain to be determined.
LncRNAs have been reported to function as 
regulators of gene expression and can directly contribute 
to aggressive cancer phenotypes. Our results suggest 
lncRNAs are significantly deregulated in CLL compared 
to normal B-cells, and can be used as prognostic 
indicators in this disease. While our results elucidate the 
role for a particular lncRNA (treRNA) in the response 
to DNA damage, it is likely that other lncRNA profiles 
will be predictive for other types of therapeutics used 
in CLL, such as B-cell receptor antagonists. Therefore 
further investigation into the function of aberrantly 
expressed lncRNA may help us further understand CLL 
pathogenesis, and provide important insight into response 
to therapy.
MATERIALS AND METHODS
Patient samples and cell culture conditions
Peripheral blood was obtained from CLL patients 
with written informed consent in accordance with the 
Declaration of Helsinki and under protocols approved 
by the Institutional Review Board of the Ohio State 
University. CLL cells and normal B-cells were isolated 
using ficoll density gradient centrifugation (Ficoll-Plaque 
Plus; Amersham Biosciences) and enriched for B-cells 
using the Rosette-Sep negative selection kit (StemCell 
Technologies) according to manufacturer protocol. 
Cryopreserved cells used in the two prognostic datasets 
were obtained from the CLL Research Consortium (CRC) 
tissue bank or from the ECOG-2997 clinical trial. Cells 
were thawed in RPMI 1640 media then washed in PBS to 
obtain cell pellets. 
The OSU-CLL cell line was grown in RPMI 1640 
media supplemented with 10% fetal bovine serum, 2mM 
L-glutamine (Invitrogen), 100U/mL penicillin, and 100ug/
mL streptomycin (Sigma). For DNA damage experiments, 
2x106 cells were incubated with vehicle (DMSO), 10uM 
fludarabine (Sigma), 2.36uM mafosfamide (Santa Cruz), 
or 10uM fludarabine plus 2.36uM mafosfamide. All 
conditions were given equivalent volumes of DMSO. 
Microarray analysis
Using ArrayStar Human LncRNA Array v2.0, 
two pools of RNA from CLL patient peripheral blood 
B-cells (n = 5 per pool) with mixed clinical and molecular 
histories, were compared to a pool of healthy donor 
B-cells (n = 6) isolated from Red Cross leukopaks. The 
normal B-cells and CLL B-cells were either unstimulated 
or stimulated with CD40 ligand (PeproTech). As an 
exploratory experiment to identify potential differentially 
expressed genes for further validation, the pooled CLL 
samples and pooled normal B-cells samples (unstimulated 
and stimulated) were treated as independent samples in the 
statistical analysis. All analyses were performed in version 
3.1.0 of the R Statistical Programming Environment. Data 
processing was performed with version 3.20.1 of the 
limma package. Background correction was performed 
using the “normal-exponential” model, and then quantile 
normalization applied. Probe-by-probe smoothed t-tests 
were used to identify genes differentially expressed 
between CLL cells and normal B-cells. In order to account 
for multiple testing, a beta-uniform-mixture (BUM) model 
was used on the p-values to estimate the false discovery 
rate (FDR). Microarray results are accessible at GEO entry 
# GSE87575.
Quantitative reverse transcription PCR (qRT-
PCR)
RNA was extracted by phenol chloroform isolation 
using TRIzol reagent (Invitrogen) then purified using the 
MirVANA kit total RNA isolation procedure (Ambion). 
Following isolation RNA was treated with Turbo DNase 
(Ambion). cDNA was prepared with SuperScript First-
Strand Synthesis System (Invitrogen). qRT-PCR to 
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validate the microarray was performed using SybrGreen 
master mix (Applied Biosystems). Prognostic datasets 
were run using TaqMan master mix (Applied Biosystems). 
Detection was performed using an ABI Prism 7700 
detection system (Applied Biosystems). LncRNA 
expression was normalized to internal control genes 
TATA-box binding protein (TBP) or Glyceraldehyde 
3-phosphate dehydrogenase (GAPDH). Custom-
designed primers were used for all SybrGreen reactions. 
Custom TaqMan primers were used for treRNA and 
ENST00000413901 TaqMan reactions, with TaqMan TBP 
primer #4326322E (ThermoFisher) used as the internal 
control. Custom designed primer sequences are provided 
in supplemental information (Supplementary Table 1). 
DeltaCT was determined by subtracting the CT value of 
the housekeeping gene from the CT value of the lncRNA.
Nuclear and cytoplasmic RNA extraction
Nuclear and cytoplasmic fractions were isolated 
using the NE-PER kit (Thermo Scientific). RNA was 
then collected using the miRVANA kit (Ambion) using 
the manufacturer protocol for cultured cells followed 
by total RNA extraction. Following isolation RNA was 
treated with Turbo DNase (Ambion). Standard PCR 
was performed for treRNA, U2, and S14 as previously 
described by Gummireddy et al [24]. 
Retrovirus vectors and generation of treRNA 
expressing cell lines
A 589bp PCR product encoding the spliced 
transcript of treRNA was cloned into the EcoRI/Not I 
sites of pRetro-tight-puro (Clontech). pRetro-tight-puro 
vector without insert was used as a control. Retrovirus was 
produced by co-transfecting the plasmid DNA of interest 
and ecotropic-helper plasmids (pVSV and pGPZ) into 
the 293T cell line using calcium phosphate precipitation. 
Doxycycline inducible Tet activator OSU-CLL cell 
line (pRetrox-Tet-on) was established according to the 
manufacturer’s protocol (Clontech). OSU-CLL-pTet-on 
cells were then infected with retrovirus by culturing for 10 
hours in the conditioned media with 8 μg/mL of polybrene. 
Cells were then washed to eliminate virus and polybrene 
and incubated in complete media for 48 h before selection 
with 1μg/mL of puromycin and 500ug/mL G418. 
Viability
Cytotoxicity was measured using 
3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) assays. Doxycycline induced OSU-
CLL treRNA and empty vector cells were plated at 
100,000 cells per well in a 96 well plate and incubated 
48 hours in fludarabine, mafosfamide, or vehicle. MTS 
reagent was then added and spectrophotometric readings 
were taken 4 hours later. Apoptosis was assessed by 
staining with Annexin V- FITC and propidium iodide (PI). 
Data were collected on a Beckman Coulter FC500 flow 
cytometer then analyzed using Kaluza software.
Migration
Cells were suspended in RPMI at 5x106cells/mL, and 
100 µl was placed in the upper chamber of a 24-transwell 
plate with a 5µm filter. Chambers were placed into wells 
containing media containing no chemokine (control), 
recombinant human CXCL12 (200ng/mL, Millipore) or 
CXCL13 (1000ng/mL, R&D systems). Migration was 
permitted for 3 hours, and cells in the lower chamber were 
collected and counted for 20 seconds on high speed on a 
Beckman Coulter FC500 flow cytometer. A 1/20 dilution 
of input cells was also determined. 
Proliferation
Proliferation was measured using the Click-iT 
Plus EdU Alexa Fluor 488 Flow Cytometry Assay Kit 
(Invitrogen) following the manufacturer protocol. Cells 
were incubated with 10uM EdU for 2 hours before 
staining.
Immunoblot
Whole cell lysates were prepared by lysing PBS-
washed OSU-CLL cell pellets in cold lysis buffer 
containing phosphatase inhibitor cocktail 1 and 2, protease 
inhibitor cocktail P8340 and 1mM phenylmethylsulfonyl 
fluoride (all from Sigma). Protein was quantified by the 
BCA method (Pierce). Protein (25ug/lane) was separated 
on 12% polyacrylamide gels and transferred onto 
nitrocellulose. After antibody incubations, proteins were 
detected with chemiluminescent substrate (Advansta) 
and quantified using a ChemiDoc system with Quantity 
One software (Bio-Rad Laboratories). The following 
antibodies were used for detection, anti-ACTB (Santa 
Cruz Biotechnologies) and anti-γH2AX (Abcam).
Single cell gel electrophoresis assay (SCGE, also 
known as comet assay)
Comet assay was performed using reagents from 
the Trevigen Comet Assay kit. Following a one hour 
drugging of OSU-CLL empty vector and treRNA, samples 
were washed with ice cold PBS then combined with 
comet agarose at a 1:10 ratio. Samples were adhered for 
30 minutes at 4oC then immersed in lysis buffer for 60 
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minutes at 4oC. Samples were then submerged in alkaline 
unwinding buffer for 30 minutes at 4oC. Samples were 
electrophoresed in alkaline running buffer, fixed with 70% 
ethanol, and then stained with SYBR gold (Fisher). Olive 
tail moment was quantified using Komet imaging software 
(Andor technologies) for 100 cells per each condition in 
three experimental replicates. 
Statistical analysis
Linear mixed effects models were applied to the 
delta CT values (relative to control: GAPDH or TBP), 
allowing for dependencies among observations from 
the same sample. From the models, which contained the 
interaction between target and cell type, differences in 
delta CT values between CLL and normal B cells for each 
target were estimated, with 95% CI, and then converted 
to fold changes. To control the overall Type I error at 
0.05, Holm’s step-down procedure was used to adjust the 
p-values from each of the individual target comparisons 
(Figure 1). 
Linear mixed effects models were also used were 
used for statistical analysis under each treatment condition 
for experiments involving viability (MTS; Figure 4a), 
western blot quantitation (log transformed, Supplementary 
Figure 5b), and olive tail moment (Figure 4d). Analyses 
were performed using SAS/STAT software, Version 9.4 of 
the SAS System for Windows (SAS Institute Inc.).
Clinical endpoints were defined as follows: Time to 
treatment (TTT) was measured from the date of diagnosis 
until the date of first treatment, censoring patients who had 
not started treatment at last follow-up. PFS was defined 
as the time from randomization until documented disease 
progression or death without progression, censoring 
patients alive and progression-free at the date of last 
reported contact, and OS was defined as the time from 
randomization until date of death, censoring patients alive 
at last contact date. Associations between lncRNAs and 
TTT, PFS, or OS were initially explored using Kaplan-
Meier plots and differences between low and high 
expression groups were evaluated with the log-rank test. 
Multivariable models were fit using Cox proportional 
hazards models. Associations between treRNA with other 
clinical and molecular features were tested using the 
Wilcoxon rank sum or Fisher’s exact tests for continuous 
and categorical variables, respectively. All tests were two-
sided and statistical significance was declared for p < 0.05.
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